There might come the time when we are finally able to leave nothing behind, at least in the context of primary PCI. The REVELATION study, soon to be published in J Am Coll Cardiol Intv, has shown that paclitaxel coated balloons resulted non inferior to drug eluting stents (DES) in terms of FFR (fractional flow<a href="https://solaci.org/en/2019/09/19/drug-coated-balloons-vs-drug-eluting-stents-in-primary-pci/" title="Read more" >...</a>
Long after myocardial revascularization guidelines had established no medical reason justifies the use of bare metal stents (BMS), along comes this study to refresh the old trials comparing drug eluting vs bare metal stents in the context of primary PCI. The problem for many countries is that primary PCI obviously occurs in the context of<a href="https://solaci.org/en/2019/07/15/des-with-bioresorbable-polymer-vs-bare-metal-stents-in-primary-pci/" title="Read more" >...</a>
Even after the US Food and Drug Administration (FDA) issued an alert on paclitaxel devices in patients with femoropopliteal artery disease, which caused the interruption of a few ongoing studies, reality indicates that the efficacy of these devices has been proven and that they are still used. The increased mortality observed in the meta-analysis that<a href="https://solaci.org/en/2019/04/09/drug-eluting-stents-vs-balloons-while-paclitaxel-is-in-the-eye-of-the-storm/" title="Read more" >...</a>
The US Food and Drug Administration (FDA) has issued an alert on the potential long-term risk of paclitaxel-coated balloons and paclitaxel-eluting stents in patients with femoropopliteal artery disease. This agency is evaluating signals of increased long-term deaths among patients with femoral or popliteal artery disease treated with paclitaxel-coated devices in a recent study. In<a href="https://solaci.org/en/2019/03/15/fda-alert-on-drug-coated-balloons-and-stents-in-femoropopliteal-artery-disease/" title="Read more" >...</a>
The rationale behind the decision to not add another layer of metal to the artery sounded attractive and this was what paved the way for drug coated balloons as an alternative strategy to treat in-stent restenosis. “We’ve already got a stent in place, we only have to dilate and leave the drug” is what we<a href="https://solaci.org/en/2019/03/14/drug-eluting-stents-vs-drug-coated-balloons-for-in-stent-restenosis/" title="Read more" >...</a>
This large cohort of patients treated with the dual therapy COMBO stent has showed excellent outcomes after one year (MASCOT Post Marketing Registry). Long term follow up is still ongoing. The COMBO stent is a new device with an abluminal sirolimus biodegradable polymer and a luminal layer of antibodies that promotes endothelial healing (anti CD34+)<a href="https://solaci.org/en/2019/03/11/abluminal-sirolimus-and-luminal-cd34-antibody-layer-is-combo-the-future-of-stents/" title="Read more" >...</a>
In this large randomized trial, there were significant differences as regards both target-lesion failure and target-vessel-related infarction, which persisted through a 2-year follow-up and favored treatment with an ultrathin-strut bioresorbable-polymer sirolimus-eluting stent (Orsiro) compared with the gold standard, a durable-polymer everolimus-eluting stent (Xience). Moreover, there were significantly lower rates of target lesion revascularization and late/very<a href="https://solaci.org/en/2019/01/04/everolimus-eluting-stents-finally-have-a-rival-and-not-just-a-non-inferior-stent/" title="Read more" >...</a>
The IMPERIAL trial compared the safety and efficacy of a nitinol self-expanding polymer-free placlitaxel-eluting stent (Zilver PTX, Cook Medical, already approved by the US Food and Drug Administration [FDA]) and a nitinol self-expanding polymer-coating placlitaxel-eluting stent (Eluvia, Boston Scientific). This was a single-blind randomized trial in patients with symptomatic intermittent claudication (Rutherford categories 2, 3, or<a href="https://solaci.org/en/2018/10/03/tct-2018-imperial-first-study-comparing-drug-eluting-stents-in-patients-with-femoropopliteal-disease/" title="Read more" >...</a>
Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress. See the presentation by Dr. Pasi Karjalainen, entitled “Bio Active Stents”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
This observational study included 231 patients from 6 sites who presented chronic total occlusions and underwent rechanneling procedures using currently available techniques, which were successful in 90% of all cases (210 patients). All patients who underwent successful rechanneling received a SYNERGY stent and most of them underwent intravascular ultrasound (90.5%). There was only 1 patient lost to clinical follow-up<a href="https://solaci.org/en/2018/05/31/europcr-2018-consistent-cto-study-rechanneling-with-current-techniques-and-synergy-stents/" title="Read more" >...</a>